Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: Experience from tropics

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 2, 2013, Pages 255-261

  Santhosh, Sampath ^a   Mittal, Bhagwant Rai ^a   Bhasin, Deepak ^a   Srinivasan, Radhika ^a   Rana, Surinder ^a   Das, Ashim ^a   Nada, Ritambhra ^a   Bhattacharya, Anish ^a   Gupta, Rajesh ^a   Kapoor, Rakesh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Chronic pancreatitis; Pancreatic cancer; Pancreatic masses; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR CLASSIFICATION;

EID: 84872813341     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12068     Document Type: Article

References (23)

1. Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer. Semin. Nucl. Med. 2006; 36: 248-256.
2. Wakabayashi H, Nishiyama Y, Otani T etal. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J. Gastroenterol. 2008; 14: 64-69.
3. John T, Greig J, Carter D etal. Carcinoma of the pancreas head and periampullary region. Ann. Surg. 1995; 221: 156-164.
4. Heinrich S, Goerres GW, Schafer M etal. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005; 242: 235-243.
5. Nichols MT, Russ PD, Chen YK. Pancreatic imaging: current and emerging technologies. Pancreas 2006; 33: 211-220.
6. Gambhir SS, Czernin J, Schwimmer J etal. A tabulated summary of the FDG PET literature. J. Nucl. Med. 2001; 42 (Suppl. 1): 1S-93S.
7. Schick V, Franzius C, Beyna T etal. Diagnostic impact of 18F-FDG PET/CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1775-1785.
8. Kauhanen SP, Komar G, Seppänen MP etal. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250: 957-963.
9. Bares R, Klever P, Hellwig D etal. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl. Med. Commun. 1993; 14: 596-601.
10. Friess H, Langhans J, Ebert M etal. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36: 771-777.
11. Bang S, Chung HW, Park SW etal. The clinical usefulness of 18-Fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J. Clin. Gastroenterol. 2006; 40: 923-929.
12. Sperti C, Bissoli S, Pasquali C etal. 18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann. Surg. 2007; 246: 932-939.
13. Takanami K, Hiraide T, Tsuda M etal. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann. Nucl. Med. 2011; 25: 501-510.
14. Yoon SN, Lee MH, Yoon JK. F-18 FDG positron emission tomography findings in primary pancreatic lymphoma. Clin. Nucl. Med. 2004; 29: 574-575.
15. Sanabe N, Ikematsu Y, Nishiwaki Y etal. Pancreatic tuberculosis. J. Hepatobiliary Pancreat. Surg. 2002; 9: 515-518.
16. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur. J. Nucl. Med. 1998; 25: 259-264.
17. Kalady MF, Clary BM, Clark LA etal. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann. Surg. Oncol. 2002; 9: 799-806.
18. Diederichs CG, Staib L, Vogel J etal. Values and limitations of FDG PET with preoperative evaluations of patients with pancreatic masses. Pancreas 2000; 20: 109-116.
19. Lowenfels AB, Maisonneuve P, Cavallini G etal. Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 1993; 328: 1433-1437.
20. van Kouwen M, Jansen JB, van Goor H etal. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 399-404.
21. Zimny M, Bares R, Fab J etal. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur. J. Nucl. Med. 1997; 24: 678-682.
22. Asagi A, Ohta K, Nasu J etal. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas 2012; doi: 10.1097/MPA.0b013e3182550d77.
23. Lin JL, Barthel JS, Keshishian J, Eikman EA, Klapman JB. Negative predictive value of positron emission tomography/computed tomography in patients with a clinical suspicion of pancreatic cancer. Pancreas 2011; 40: 653-656.